Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTRAY EXTENSION: open-label extension of weight-banded sotatercept in pulmonary arterial hypertension
CTR20252035Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co.. Started Jun 2025; status: active.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20252035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252035.